<?xml version="1.0" encoding="UTF-8"?><ns2:project xmlns:ns1="http://gtr.rcuk.ac.uk/gtr/api" xmlns:ns2="http://gtr.rcuk.ac.uk/gtr/api/project" xmlns:ns3="http://gtr.rcuk.ac.uk/gtr/api/fund" xmlns:ns4="http://gtr.rcuk.ac.uk/gtr/api/person" xmlns:ns5="http://gtr.rcuk.ac.uk/gtr/api/project/outcome" xmlns:ns6="http://gtr.rcuk.ac.uk/gtr/api/organisation" ns1:created="2026-06-22T07:57:45Z" ns1:href="http://gtr.ukri.org/gtr/api/projects/4D6F1189-FA0A-49BE-89A8-BAF213EF7E21" ns1:id="4D6F1189-FA0A-49BE-89A8-BAF213EF7E21"><ns1:links><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/2043BC58-3F2F-402A-9102-C15384E21A33" ns1:rel="LEAD_ORG"/><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/BFE41CB6-4B8A-4082-B96B-3DFEFE793924" ns1:rel="PARTICIPANT_ORG"/><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/2043BC58-3F2F-402A-9102-C15384E21A33" ns1:rel="PARTICIPANT_ORG"/><ns1:link ns1:end="2016-12-31T00:00:00Z" ns1:href="http://gtr.ukri.org/gtr/api/funds/DDAAF1F3-023E-4F8A-B376-9DAAC51E90E0" ns1:rel="FUND" ns1:start="2016-01-01T00:00:00Z"/></ns1:links><ns2:identifiers><ns2:identifier ns2:type="RCUK">132125</ns2:identifier></ns2:identifiers><ns2:title>Project title: Refining oxidative enzyme systems from talented microorganisms for industrial biocatalysis</ns2:title><ns2:status>Closed</ns2:status><ns2:grantCategory>Feasibility Studies</ns2:grantCategory><ns2:leadFunder>Innovate UK</ns2:leadFunder><ns2:abstractText>Microorganisms and their cytochrome P450 (CYP) oxidative enzymes can be used for production of drug

and agrochemical metabolites, or to produce new derivatives of early-stage lead compounds with

improved properties. Hypha Discovery’s panel of wild-type bacteria is highly effective in producing

oxidized metabolites by whole-cell biotransformation but has limitations with regard to the speed and

specificity of production. This challenge will be addressed in collaboration with UCL by introducing

individual CYP enzymes from the six most talented members of the panel into E. coli and S. lividans

chassis as three-gene operons using ferredoxin and ferredoxin reductase genes with broad functional

activity. The catalytic activities of the resulting recombinant strains will be compared with those of the

wild-type parents by testing against a diverse substrate panel. Cell-free enzyme extract preparations will

then be prepared and assembled into a kit that can be used for testing in client laboratories.</ns2:abstractText></ns2:project>